New Data Ahead Of Launch Could Help Strengthen Symbravo’s Position In Migraine

Results from the Phase III EMERGE study showed that Axsome’s recently approved Symbravo is effective in patients dissatisfied with oral CGRP inhibitors.

Headache
• Source: Shutterstock

Fresh off its approval from the US Food and Drug Administration, Axsome Therapeutics’ migraine drug Symbravo (meloxicam and rizatriptan) stands to potentially strengthen its position in a crowded marketplace, with data showing it can treat patients who have not responded well to the CGRP inhibitors that currently dominate that market.

Axsome said 24 February that the open-label Phase III EMERGE trial of Symbravo among patients experiencing inadequate response to oral...

More from Clinical Trials

Vertex’s Pain Drug Failure Adds To Investor Doubts

 

A Phase II trial to develop a second NaV1.8 pain signal inhibitor for acute pain has failed and the US FDA has given a thumbs down on Journavx’s path to broader use in peripheral neuropathic pain.

Cardiff Pushes Towards Colorectal Cancer Phase III As Funding Questions Loom

 
• By 

Cardiff Oncology is open to going it alone, a partnership and even an exit as the San Diego, CA-based firm tries to push its PLK1 inhibitor through late-stage development.

Aurigene Oncology CEO On Biotech Valuations, CAR-Ts And Reimbursement Models

 

Aurigene Oncology CEO talks in this audio interview about the tough biotech funding environment, pipeline assets including a CAR-T therapy in Phase II, "hybrid" manufacturing, outcome-based reimbursement and the promise of bispecifics and multispecifics, including Akeso's PD-1/VEGF bispecific.

Allogene Sticks With Standard Lymphodepletion In CAR-T Trial After Patient Death

 

The company said it will no longer use ALLO-647 after a patient developed a fatal adenovirus infection, and it will pursue further development of its Dagger technology to minimize or eliminate the need for lymphodepletion.

More from R&D

BioNTech Outlines Development Plan For PD-L1xVEGF-Targeting BNT-327

 

The company, with partner Bristol Myers Squibb, has a three-wave development strategy for BNT-327: “establish, combine, broaden.”

AstraZeneca’s Tagrisso Mountain Grows, But The Climb Will Be Challenging

 
• By 

The UK major continues to post promising data readouts that further emphasize the safety and efficacy of its blockbuster lung cancer drug, but competition from J&J's Rybrevant is ramping up, and capable challengers are emerging.

Pipeline Watch: Ten Approvals And Fourteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.